-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15, Zhejiang Medicine announced that it had recently received a "Drug Supplementary Application Approval Notice" of 0.
Vancomycin is a narrow-spectrum glycopeptide antibiotic produced by a strain of Streptomyces orientalis
Bacteria effective for methicillin-resistant Staphylococcus aureus and other bacterial infections caused by: sepsis, a sense of infectious endocarditis, osteomyelitis, arthritis, burns, surgical trauma and other superficial secondary infections, pneumonia , lung abscess, empyema, peritonitis, meningitis
At present, Zhejiang Medicine has invested about 6 million yuan in research and development expenses for the evaluation of the consistency of vancomycin hydrochloride for injection .
The company's 2020 sales revenue of vancomycin hydrochloride for injection is 193,354,400 yuan .